Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer

Fig. 3

CXCL12 is a clinically relevant TEC marker. A Volcano plot representing a differential analysis of NEC versus TEC. B Representative immunofluorescence staining (CD31 and CXCL12) of NEC and TEC. Note the high expression levels of CXCL12 in the tumor vasculature. C Kaplan–Meier curves where patients are stratified based on the high or low expression of CXCL12. n = 422, source TCGA dataset. The CXCL12 expression cutoff was determined using the R package “maxstat”. The cut-off point for CXCL12 expression was calculated as a log2 expression value of 17.626. D Violin plots visualizing the log2 fold-change distribution in gene expression (gray area) in murine and human tumor EC versus their counterpart normal healthy EC. The red dot indicates where CXCL12 is located in the distribution. Data are based on a meta-analysis of publicly available transcriptome datasets

Back to article page

Molecular Cancer

ISSN: 1476-4598